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THE development of diabetes mellitus in the renal 
transplant population was first reponed by Starzi in 
1964 and was attributed to the use of steroids.' Since then. 
posttransplant diabetes mellitus has been associated with 
the use of other immunosuppressive agents. such as cy-
closporine (CyA). Because FK 506 is also thought to be 
diabetogenic.:: we retrospectively looked at the incidence 
of new onset diabetes mellitus in patients treated primarily 
with either FK 506 or Cy A in a randomized trial of kidney 
transplantations done at the University of Pittsburgh from 
- 1990 to May 1991. 
MATERIAL AND METHODS 
Patient Population 
The criteria for randomization include (I) primary transplants. (2) 
patients between age 16 and 60 years. (3) PRA <40%. and (4) no 
hepatic or cardiac dysfunction. Fifty-five patients were entered 
into the study from February 20. 1990 to May I. 1991. Twelve 
patients who were known diabetics prior to transplantation were 
excluded from analysis. Nine patients randomized to CyA and 
prednisone were switched to FK 506 and prednisone due to 
resistant rejection. These patients were therefore not included in 
the analysis. The final evaluation was then conducted on a group 
of 34 patients: 20 were treated with FK 506 and prednisone and 14 
received Cy A and prednisone. 
Diabetes mellitus was defined as a fasting blood sugar greater 
than 150 mgidL obtained on three separate occasions. Abnormal 
plasma glucose levels occurring while a steroid taper was being 
administered were not considered as a mamfestation of diabetes if 
glucose levels returned to normal at the end of the steroid taper. 
Immunosuppression 
Prior to August of 1990. FK 506 was given in two daily doses of 
0.075 mgikg/dose over a 4-hour infusion. Patients received 20 mg 
of IV methylprednisolone in the recovery room and 20 mg of oral 
prednisone or IV methylprednisolone daily thereafter. CyA was 
given at 2 mglkgldose twice a day as a 2-hour infusion. After 
August 1990. FK 506 was changed to a continuous IV infusion 
over 24 hours of 0.1 mglkgld with a 6-day steroid recyclefollowing 
an intraoperative bolus of 1.000 mg of IV methylprednisolone. 
The eyA dosage remained the same. 
Rejection Episodes 
Rejection as diagnosed by biopsy was treated with 1.000 mL of I V 
methylprednisolone with or without a 6-day steroid taper. 
Analysis 
Statistical analysis was calculated by Fisher Exact Test. Differ-
ences of P < .05 were considered significant, 
RESULTS 
Of the 24 patients analyzed. 4 out of 20 patients receiving 
FK 506 primarily became diabetic (20%) within 1 month 
after kidney transplantation. All four patients required 
insulin therapy for management of their hyperglycemia. 
FK 506 dosages were also decreased and steroids were 
tapered to zero when tolerated. One patient had concom-
itant rejection at the time of diagnosis of diabetes mellitus 
and had to be treated with extra steroids: all three remain-
ing patients had their steroid therapy discontinued by I 
week. in two of the patients. and by 4 week.s in the third 
case. Insulin therapy was discontinued at 4 and 6 weeks in 
two cases (50%) with one patient switching to a low dose 
oral hyperglycemic agent. The remaining two cases are 
still on insulin therapy at 12 months and 14 months 
following initiation of treatment. 
Within the CyA group. the onset of new diabetes was 
seen in lout of 14 patients (7%). This patient developed 
diabetes within 2 weeks of transplantation but required 
only an oral hyperglycemic agent. 
In analyzing both groups of patients. we find that age 
may play a role in the onset and persistence of diabetes 
mellitus. Two patients ages less than 40 years had resolu-
tion of diabetes: those older than 40 years had persistence 
of insulin-dependent diabetes beyond I year follow-up 
(two patients). One long-term diabetic patient who is off 
steroid therapy was found to have a HLA DR4 typing; no 
other markers were found among the remaining patients. 
Within the group of patients originally on Cy A but 
switched to FK 506 (nine patients) there was one case of 
new onset diabetes mellitus. Since this patient was inten-
sively treated for persistent rejection and received both 
main immunosuppressive drugs. he was not included in the 
final analysis. 
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DISCUSSION 
The occurrence of diabetes mellitus after kidney transplan-
tation has been described in the literature as between 4% 
and 15%.3-5 The incidence of diabetes mellitus with CyA is 
known to be higher than when compared with those 
receiving azathioprine and steroids. Since the first clinical 
trials of FK 506 it has been found that this drug alters 
carbohydrate metabolism by inhibiting insulin secretion 
and increasing peripheral insulin resistance. These charac-
teristics are also true for Cy A. The ability to use FK 506 
with very low doses or no doses of steroids may lead to 
reduction in the incidence of posttransplant diabetes mel-
litus. 
Our findings of a 20% incidence of new onset diabetes 
mellitus with FK 506 when compared with 7% incidence 
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With CyA is not statistically significant. Since half of this 
new onset insulin dependence was reversible. the true 
incidence was 10%. similar to what has been seen with 
CyA.3-5 It is important to realize. however. that diabeto 
genesis remains a significant side effect of FK 506. 
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